Patents by Inventor Mark Seefeld

Mark Seefeld has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20160287561
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: April 13, 2016
    Publication date: October 6, 2016
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • Publication number: 20150152092
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: December 8, 2014
    Publication date: June 4, 2015
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • Patent number: 8946278
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 22, 2013
    Date of Patent: February 3, 2015
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Dennis S. Yamashita, Kenneth C. McNulty
  • Publication number: 20130231378
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: February 22, 2013
    Publication date: September 5, 2013
    Applicant: GlaxoSmithKline LLC
    Inventors: Mark A. SEEFELD, Meagan B. Rouse, Dirk A. Heerding, Dennis S. Yamashita, Kenneth C. McMulty
  • Patent number: 8410158
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: April 2, 2013
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • Patent number: 8273782
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Grant
    Filed: February 7, 2008
    Date of Patent: September 25, 2012
    Assignee: GlaxoSmithKline LLC
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • Patent number: 8173646
    Abstract: Compounds of the Formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: July 6, 2010
    Date of Patent: May 8, 2012
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas, Walter E. Dewolf, Jr., Dalia R. Jakas
  • Patent number: 8153652
    Abstract: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: April 10, 2012
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Walter J. Burgess, Dalia R. Jakas, William F. Huffman, William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas
  • Publication number: 20110190283
    Abstract: Compounds of the Formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.
    Type: Application
    Filed: July 6, 2010
    Publication date: August 4, 2011
    Inventors: William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas, Walter E. DeWolf, JR., Dalia R. Jakas
  • Publication number: 20110160256
    Abstract: Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: June 24, 2009
    Publication date: June 30, 2011
    Inventors: Meagan B. Rouse, Mark A. Seefeld
  • Publication number: 20110160255
    Abstract: Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: June 24, 2009
    Publication date: June 30, 2011
    Inventors: Meagan B. Rouse, Mark A. Seefeld
  • Publication number: 20110129455
    Abstract: Invented are novel pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: June 24, 2009
    Publication date: June 2, 2011
    Inventors: Hong Lin, Meagan B. Rouse, Mark A. Seefeld, Dennis S. Yamashita, Ren Xie
  • Publication number: 20110098277
    Abstract: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.
    Type: Application
    Filed: April 12, 2010
    Publication date: April 28, 2011
    Inventors: Walter J. Burgess, Dalia Jakas, William F. Huffman, William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas
  • Publication number: 20110098221
    Abstract: Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: June 24, 2009
    Publication date: April 28, 2011
    Inventors: Hong Lin, Meagan B. Rouse, Mark A. Seefeld, Ren Xie
  • Publication number: 20110092423
    Abstract: Invented are novel hetero-pyrrole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: June 24, 2009
    Publication date: April 21, 2011
    Inventors: Meagan B. Rouse, Mark A. Seefeld
  • Publication number: 20110071182
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: December 23, 2008
    Publication date: March 24, 2011
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding
  • Publication number: 20100267759
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: February 7, 2008
    Publication date: October 21, 2010
    Applicant: SMITHKLINE BEECHAM CORPORATION
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding, Simon Peace, Dennis S. Yamashita, Kenneth C. McNulty
  • Patent number: 7790716
    Abstract: Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: March 12, 2009
    Date of Patent: September 7, 2010
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas, Walter E. Dewolf, Jr., Dalia R. Jakas
  • Patent number: 7741339
    Abstract: Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.
    Type: Grant
    Filed: June 25, 2007
    Date of Patent: June 22, 2010
    Assignee: Affinium Pharmaceuticals, Inc.
    Inventors: Walter J. Burgess, Dalia R. Jakas, William F. Huffman, William H. Miller, Kenneth A. Newlander, Mark A. Seefeld, Irene N. Uzinskas
  • Publication number: 20100041726
    Abstract: Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.
    Type: Application
    Filed: October 1, 2009
    Publication date: February 18, 2010
    Inventors: Mark A. Seefeld, Meagan B. Rouse, Dirk A. Heerding